A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
about
Bortezomib for the treatment of multiple myelomaFifty years of melphalan use in hematopoietic stem cell transplantationRetinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cellsArsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6Bortezomib in multiple myeloma: systematic review and clinical considerations.Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies.Not too little, not too much-just right! (Better ways to give high dose melphalan).Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.Opposing effects of low versus high concentrations of water soluble vitamins/dietary ingredients Vitamin C and niacin on colon cancer stem cells (CSCs).Bayesian survival analysis in clinical trials: What methods are used in practice?Induction of cellular and molecular Immunomodulatory pathways by vitamin E and vitamin C.Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid.Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
P2860
Q24185881-918F9429-07F1-435A-BBE1-04D68A52A965Q26824498-4025E412-8B1B-4B70-ACA5-8AD184994E71Q28393380-FCF5854A-4AA3-4001-A760-280BD643E437Q28481142-B8A66CDA-2FA2-4F8A-AB98-E7F99C85EBDDQ33982728-159F0AAF-705C-460E-A1E1-1E71A5ECD680Q34115051-D943B565-B2CB-437F-823A-8C4A30E333F6Q38095526-53BC8291-12C4-4D23-B33A-33D6C171309FQ38104413-461E6615-696D-4A3F-98D9-E8D49B9206B8Q38240941-AD36CDAC-38D3-451A-A725-FC4795477446Q38253354-EE7E7845-A777-43FE-8F56-CA50353CD791Q38649985-FECBBFB8-7288-4832-9A4E-35D1BC9FF24CQ38978314-532920F0-51A0-4517-B396-0C9066A97361Q40047014-50A4F84D-91FE-4779-AEC9-A98BC67D6305Q42009130-513968B7-F70F-45C9-9F2C-8B080E21A5D0Q47238436-54C0D79F-BEA9-46EF-A2A7-2AA073391585Q47630577-9E3BBDB0-2510-48B8-B6CC-EDFE7C7C2CB5
P2860
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@ast
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@en
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@nl
type
label
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@ast
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@en
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@nl
prefLabel
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@ast
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@en
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@nl
P2093
P2860
P356
P1433
P1476
A randomized phase 2 trial of ...... c trioxide, and ascorbic acid.
@en
P2093
Hassan Khan
Jatin J Shah
Manish Sharma
Michael Wang
Muzaffar H Qazilbash
Peter F Thall
Qaiser Bashir
Richard E Champlin
Roland L Bassett
P2860
P304
P356
10.1002/CNCR.26517
P407
P577
2011-09-01T00:00:00Z